

Michael J Schell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10671081/publications.pdf>

Version: 2024-02-01

56
papers

5,059
citations

109321

35
h-index

155660

55
g-index

56
all docs

56
docs citations

56
times ranked

7191
citing authors

#	ARTICLE	IF	CITATIONS
1	Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 252-259.	1.9	4
2	Circulating Immunosuppressive Regulatory T Cells Predict Risk of Incident Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 2021, 8, 735585.	2.6	1
3	Modeling precision genomic-based radiation dose response in rectal cancer. <i>Future Oncology</i> , 2020, 16, 2411-2420.	2.4	2
4	Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 1981.	7.1	0
5	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. <i>JAMA Oncology</i> , 2020, 6, 888.	7.1	293
6	Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant <i>APC</i> and <i>TP53</i> Subpopulations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1141-1152.	2.5	15
7	Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. <i>British Journal of Cancer</i> , 2019, 120, 791-796.	6.4	16
8	Green tea extract for prevention of prostate cancer progression in patients on active surveillance. <i>Oncotarget</i> , 2018, 9, 37798-37806.	1.8	9
9	A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. <i>Lancet Oncology</i> , The, 2017, 18, 202-211.	10.7	377
10	Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints. <i>Biometrics</i> , 2017, 73, 687-695.	1.4	6
11	Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. <i>Oncotarget</i> , 2017, 8, 99093-99103.	1.8	8
12	Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. <i>Oncotarget</i> , 2016, 7, 70794-70802.	1.8	41
13	A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. <i>Nature Communications</i> , 2016, 7, 11743.	12.8	170
14	Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 712-720.	7.0	225
15	Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. <i>Cancer Prevention Research</i> , 2015, 8, 879-887.	1.5	102
16	Co-Evolution of Somatic Variation in Primary and Metastatic Colorectal Cancer May Expand Biopsy Indications in the Molecular Era. <i>PLoS ONE</i> , 2015, 10, e0126670.	2.5	36
17	Improved survival modeling in cancer research using a reduced piecewise exponential approach. <i>Statistics in Medicine</i> , 2014, 33, 59-73.	1.6	24
18	Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2404-2412.	1.6	143

#	ARTICLE	IF	CITATIONS
19	12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?. <i>Scientific Reports</i> , 2012, 2, 765.	3.3	307
20	Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. <i>Statistics in Biopharmaceutical Research</i> , 2012, 4, 348-356.	0.8	8
21	Preliminary indication of survival benefit from <i>ERCC1</i> and <i>RRM1</i> -tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. <i>Cancer</i> , 2012, 118, 2525-2531.	4.1	45
22	<i>ERCC1</i> and <i>RRM1</i> in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis. <i>American Journal of Pathology</i> , 2011, 178, 69-78.	3.8	59
23	Optimism bias leads to inconclusive resultsâ€”an empirical study. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 583-593.	5.0	45
24	Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. <i>International Journal of Cancer</i> , 2011, 129, 1963-1969.	5.1	100
25	ID1 Facilitates the Growth and Metastasis of Non-Small Cell Lung Cancer in Response to Nicotinic Acetylcholine Receptor and Epidermal Growth Factor Receptor Signaling. <i>Molecular and Cellular Biology</i> , 2011, 31, 3052-3067.	2.3	58
26	Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Nonâ€”Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1387-1394.	1.6	184
27	Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ <i>RRM1</i> and <i>ERCC1</i> Protein Levels for Response Prediction in Nonâ€”Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5808-5815.	1.6	164
28	Phase 2 trial of docetaxel and gefitinib in the firstâ€”line treatment of patients with advanced nonsmallâ€”cell lung cancer (NSCLC) who are 70 years of age or older. <i>Cancer</i> , 2008, 112, 2021-2029.	4.1	25
29	Decision-Making When Data and Inferences Are Not Conclusive: Risk-Benefit and Acceptable Regret Approach. <i>Seminars in Hematology</i> , 2008, 45, 150-159.	3.4	26
30	Evidence-based Target Recall Rates for Screening Mammography ^{>1</sup>. <i>Radiology</i>, 2007, 243, 681-689.}	7.3	87
31	Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. <i>Lung Cancer</i> , 2006, 51, 237-243.	2.0	15
32	Continuous Toxicity Monitoring in Phase II Trials in Oncology. <i>Biometrics</i> , 2005, 61, 540-545.	1.4	62
33	Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4653-4657.	7.0	457
34	Steroid 5 α -Reductase Isozymes I and II in Recurrent Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4365-4371.	7.0	166
35	Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 47, 253-259.	2.0	60
36	Recall and detection rates in screening mammography. <i>Cancer</i> , 2004, 101, 2710-2711.	4.1	3

#	ARTICLE	IF	CITATIONS
37	The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. <i>Cancer</i> , 2003, 98, 779-788.	4.1	130
38	Factors Predicting Successful Needle-Localized Breast Biopsy. <i>Academic Radiology</i> , 2003, 10, 601-606.	2.5	32
39	Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1335-1343.	1.6	297
40	Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. <i>Cancer</i> , 2002, 95, 1265-1273.	4.1	55
41	Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma. <i>Cancer</i> , 2001, 92, 1213-1223.	4.1	160
42	Association of Recall Rates with Sensitivity and Positive Predictive Values of Screening Mammography. <i>American Journal of Roentgenology</i> , 2001, 177, 543-549.	2.2	125
43	Hormone-related Factors and Risk of Breast Cancer in Relation to Estrogen Receptor and Progesterone Receptor Status. <i>American Journal of Epidemiology</i> , 2000, 151, 703-714.	3.4	232
44	Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation. <i>Lung Cancer</i> , 2000, 28, 1-10.	2.0	66
45	Second-Line Gemcitabine in Refractory Stage IV Non-Small-Cell Lung Cancer: A Phase II Trial. <i>Clinical Lung Cancer</i> , 2000, 2, 133-138.	2.6	15
46	The Influence of a Low-Fat Diet on Incidence and Severity of Migraine Headaches. <i>Journal of Women's Health and Gender-Based Medicine</i> , 1999, 8, 623-630.	1.5	70
47	In vivo percutaneous absorption of boron as boric acid, borax, and disodium octaborate tetrahydrate in humans. <i>Biological Trace Element Research</i> , 1998, 66, 101-109.	3.5	12
48	In vitro percutaneous absorption of boron as boric acid, borax, and disodium octaborate tetrahydrate in human skin. <i>Biological Trace Element Research</i> , 1998, 66, 111-120.	3.5	5
49	In Vivo Percutaneous Absorption of Boric Acid, Borax, and Disodium Octaborate Tetrahydrate in Humans Compared to in Vitro Absorption in Human Skin from Infinite and Finite Doses. <i>Toxicological Sciences</i> , 1998, 45, 42-51.	3.1	46
50	The Reduced Monotonic Regression Method. <i>Journal of the American Statistical Association</i> , 1997, 92, 128-135.	3.1	52
51	Adverse prognostic features in 251 children treated for acute myeloid leukemia. <i>Medical and Pediatric Oncology</i> , 1993, 21, 1-7.	1.0	19
52	Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 308-313.	4.7	105
53	Long-term follow-up of parental adjustment following a child's death at home or hospital. <i>Cancer</i> , 1989, 63, 988-994.	4.1	70
54	Immunohistochemical expression of neuron-specific enolase and leu 7 in Ewing's sarcoma of bone. <i>Cancer</i> , 1989, 64, 1266-1273.	4.1	64

#	ARTICLE	IF	CITATIONS
55	Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children. <i>Cancer</i> , 1988, 61, 589-592.	4.1	47
56	Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. <i>Cancer</i> , 1987, 59, 374-379.	4.1	114